Drugs / Icariin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06900478 | Mar 2025 → Jun 2026 overdue | hepatocellular carcinoma | Hua Li | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01979133 | Oct 2013 → Jun 2015 | bipolar disorder, substance-related disorder | University of Texas Southwestern Medical Center | Completed | Mixed |
| Phase not applicable1 trial | ||||||
| — | NCT07076784 | Mar 2023 → Dec 2025 | acne | Seoul National University Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02112123 Comparator | Apr 2014 → Sep 2016 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Icariin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02112123 ↗ |
| Known as | Epimedii herba icariin | ChEMBL registry synonym — accepted as the source's own label CHEMBL553204 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “traditionally used in oriental medicine as an herbal remedy and dietary tincture” NCT07076784 ↗ |
| Route | Oral | “Icariin given at 100 mg/day (qd po) for 5 days” NCT02112123 ↗ |